Opinion/decision on a Paediatric investigation plan (PIP): Kyntheum, brodalumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0212/2023

EMEA-000902-PIP01-10-M01

Opinion/decision on a Paediatric investigation plan (PIP): Ponvory, ponesimod, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology;Other, PIP number: P/0234/2023

EMEA-000551-PIP04-21-M02

Opinion/decision on a Paediatric investigation plan (PIP): Noxafil, posaconazole, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0200/2023

EMEA-000347-PIP02-16-M05

EMEA-000207-PIP01-08-M08

Referral: Hydroxyprogesterone caproate-containing medicinal products, hydroxyprogesterone caproate, associated names: Lentogest,Progesterone Retard Pharlon,Proluton Depot Article 31 referrals CMDh final position, 05/07/2024

2023 annual report of the European Medicines Agency

Pharmacovigilance fees payable to the European Medicines Agency